Search results for "ST-elevation myocardial infarction"

showing 4 items of 4 documents

Lower ST-elevation myocardial infarction incidence during COVID-19 epidemic in Northern Europe

2020

We compared the ST elevation myocardial infarction (STEMI) incidence during COVID-19 pandemic (March 2020) to January-February 2020 and to same time period in earlier years 2017-2019 in five Nordic-Baltic tertiary centers. During 2017-2019, there were no marked differences in STEMI incidence between January, February and March. During 2020, there was an average drop of 32% in STEMI incidence in March. The isolation measures may decrease the risk for respiratory virus infection and contribute to the lower STEMI incidence and that we might benefit from firmer suggestions on hand hygiene and social distancing during flu season at least among high-risk individuals.

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)media_common.quotation_subject030204 cardiovascular system & hematologyScandinavian and Nordic CountriesTertiary Care Centers03 medical and health sciences0302 clinical medicineSt elevation myocardial infarctionHygieneRespiratory virus infectionPandemicFlu seasonMedicineHumanscardiovascular diseases030212 general & internal medicinemedia_commonRetrospective Studiesbusiness.industryIncidence (epidemiology)IncidenceCOVID-19Latvia3. Good healthsurgical procedures operativeST-elevation myocardial infarctionincidenceST Elevation Myocardial InfarctionbusinessCardiology and Cardiovascular MedicineDemography
researchProduct

Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? …

2016

IF 4.638; International audience; Background: Few clinical trials have focused on populations with a history of distant myocardial infarction (MI). The PEGASUS trial assessed the impact of dual antiplatelet therapy in such patients, selected by enrichment criteria of high cardiovascular risk. Whether the PEGASUS population reflects the risk of a broader post-MI population is questionable. We analyzed whether 4-year mortality of a routine-practice population would differ according to the inclusion and exclusion criteria used in PEGASUS.Methods: FAST-MI is a nationwide French registry recruiting acute MI patients in November 2005; 2490 patients alive and without recurrent MI at one year were …

MaleTicagrelorMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery disease0302 clinical medicineRandomized controlled trialRisk FactorslawSecondary PreventionRegistriesSurvivors030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as TopicAged 80 and overeducation.field_of_studyReperfusion therapyEvidence-Based PharmacotherapyMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemST-elevation myocardial infarctionPopulation SurveillanceInclusion and exclusion criteriaFemaleFranceAtherothrombotic EventsCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulationAcute St-ElevationAcute myocardial infarctionVorapaxar03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansMortalityeducationSelection (genetic algorithm)AgedAspirinbusiness.industryPatient SelectionAntiplatelet therapymedicine.diseaseComorbidityClinical trialAdherencePhysical therapyTherapybusinessFollow-Up Studies
researchProduct

Impact of routine invasive strategy on outcomes in patients with non-ST-segment elevation myocardial infarction during 2005–2014: A report from the P…

2020

Background: Non-ST-segment elevation myocardial infarction (NSTEMI) has become the most frequently encountered type of myocardial infarction. The patient clinical profile and management has evolved over the past decade. As there is still a scarcity of data on the latest trends in NSTEMI, changes herein were observed and assessed in the treatment and outcomes in Poland between 2005 and 2014. Methods: A total of 197,192 patients with NSTEMI who enrolled in the Polish Registry of Acute Coronary Syndromes (PL-ACS) between 2005 and 2014 were analyzed. In-hospital and 12-month mortality were assessed. Results: Coronary angiography use increased from 35.8% in 2005–2007 to 90.7% in 2012–2014 (p < 0…

Malemedicine.medical_specialtyInvasive strategyMultivariate analysismedicine.medical_treatmentnon-ST-elevation myocardial infarctionMyocardial InfarctionClinical CardiologyoutcomesCoronary AngiographyVentricular Function Lefttemporal trendsPercutaneous Coronary InterventionRisk FactorsInternal medicinemedicineST segmentHumansinvasive strategyMyocardial infarctionRegistriesAcute Coronary SyndromeChildNon-ST Elevated Myocardial Infarctionbusiness.industryMortality ratePercutaneous coronary interventionStroke VolumeGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseConfidence intervalTreatment OutcomeCardiologyFemalePolandCardiology and Cardiovascular Medicinebusiness
researchProduct

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor
researchProduct